{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:53:38Z","timestamp":1791651218177,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neuroendocrine tumors are part of a heterogeneous group of tumors located in organs such as the gastrointestinal tract (GIT), lungs, thymus, thyroid, and adrenal glands. The most prevalent sites are the small intestine, cecal appendix, and pancreas. More than 50% of these tumors are associated with metastases at the time of diagnosis. Neuroendocrine tumors are classified according to the degree of cell differentiation and the histopathological proliferation index of the lesion. Neuroendocrine tumors can be well differentiated or poorly differentiated. G3 tumors are characterized by Ki-67 expression greater than 20% and can be either well differentiated (G3 NET) or poorly differentiated (G3 NEC). Neuroendocrine carcinoma (NEC G3) is subdivided into small-cell and large-cell types. When neuroendocrine tumors present clinical and compressive symptoms, carcinoid syndrome is evident. Carcinoid syndrome occurs when the tumor produces neuroendocrine mediators that cannot be metabolized by the liver due to either the size of the tumor or their secretion by the liver itself. Several therapeutic strategies have been described for the treatment of metastatic neuroendocrine tumors, including curative or palliative surgical approaches, peptide receptor radionuclide therapy, percutaneous therapy, systemic chemotherapy, and radiotherapy. Liver surgery is the only approach that can offer a cure for metastatic patients. Liver metastases must be completely resected, and in this context, orthotopic liver transplantation has gained prominence for yielding very promising outcomes in selected cases. The aim of this study is to review the literature on OLT as a form of treatment with curative intent for patients with gastroenteropancreatic neuroendocrine tumors with liver metastasis.<\/jats:p>","DOI":"10.3389\/fonc.2022.1001163","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T11:12:07Z","timestamp":1675941127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Liver transplantation in gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.3389","volume":"12","author":[{"given":"Eduardo de Souza M.","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila V. Garcia","family":"Kyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Pedreira Tavares","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Savattone","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo de Oliveira","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Gir\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"C\u00e9sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munique","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda","family":"Monachesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Cristina","family":"Tavares de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington","family":"Andraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando Jorge M.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000503721","article-title":"Neuroendocrine neoplasm of the small bowel and pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplantation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4","article-title":"Cardinoid tumors. An analysis of 2,837 cases","volume":"36","author":"Godwin","year":"1975","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the united states","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021","volume":"19","author":"Shah","year":"2021","journal-title":"NCCN Clin Pract Guidelines Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70174-5","article-title":"ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis","volume":"116","author":"Rindi","year":"1999","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-021-09676-z","article-title":"Challenges in high-grade neuroendocrine neoplasms and mixed Neuroendocrine\/Non-neuroendocrine neoplasms","volume":"32","author":"Rosa, Stefano","year":"2021","journal-title":"Endocr Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s004280100540","article-title":"Genetic evidence for the multi-step progression of meixed glandular-neuroendocrine gastric carcinomas","volume":"440","author":"Kim","year":"2002","journal-title":"Virchows Arch"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s004280000337","article-title":"Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs","volume":"438","author":"Helpap","year":"2001","journal-title":"Virchows Arch"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics5020119","article-title":"Neuroendocrine carcinomas of the gastroenteropacreatic system: A comprehensive review","volume":"5","author":"Ilett","year":"2015","journal-title":"Diagnostics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.trre.2021.100595","article-title":"Neuroendocrine liver metastases: The role of liver transplantation","volume":"35","author":"D'Amico","year":"2021","journal-title":"Transplant Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases treatment of neuroendocrine liver metastases","volume":"121","author":"Frilling","year":"2015","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2020.04.02","article-title":"Neuroendocrine liver metastases: A contemporary review of treatment strategies","volume":"9","author":"Cloyd","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.2891","article-title":"Transplantation and surgical strategies in patients with neuroendocrine liver metastases: Protocol of four systematic reviews","volume":"2","author":"Stump","year":"2013","journal-title":"JMIR Res Protoc"},{"key":"B20","article-title":"Liver metastases from neuroendocrine tumor: Transplantation","author":"Andraus","year":"2020","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15576","article-title":"Liver transplant for hepatocellular carcinoma in the united states: Evolving trends over the last three decades","volume":"20","author":"Puigveh\u00ed","year":"2020","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24791","article-title":"Liver transplantation for colorecal liver metastasis: Survival without recurrence can be achieved","volume":"23","author":"Toso","year":"2017","journal-title":"Liver Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i20.2152","article-title":"Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours","volume":"24","author":"Frilling","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v10.i7.517","article-title":"Medeiros KAA Large primary hepatic gastrinoma in young patient treated with trisegmentectomy: A case report","volume":"10","author":"Pipek","year":"2018","journal-title":"World J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3523-y","article-title":"Liver transplantation for unresectable neuroendocrine tumor liver metastases","volume":"21","author":"Rossi","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23973","article-title":"Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables","volume":"112","author":"Sher","year":"2015","journal-title":"J Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000281","article-title":"Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more","volume":"21","author":"Kalra","year":"2016","journal-title":"Co-transplantation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2017.12.11","article-title":"Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology","volume":"7","author":"Shimata","year":"2017","journal-title":"Gland Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003802","article-title":"Postrecurrence survival after liver transplantation for liver metastases from neuroendocrine tumors","volume":"105","author":"Sposito","year":"2021","journal-title":"Transplantation"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17156","article-title":"Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria","volume":"22","author":"Maspero","year":"2022","journal-title":"Am J Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.23736\/S0026-4733.19.08119-7","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors","volume":"74","author":"Spolverato","year":"2019","journal-title":"Minerva Chir"},{"key":"B32","article-title":"Liver review board guidance documents","author":"Callahan","year":"2016","journal-title":"UNOS Policy Department"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2019.06.02","article-title":"Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection","volume":"9","author":"Armstrong","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1126","article-title":"Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography","volume":"26","author":"Koopmans","year":"2008","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28760","article-title":"Therapeutics strategies for neuroendocrine liver metastases","volume":"121","author":"Frilling","year":"2014","journal-title":"ACS Journals"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Fa-DOTATOC positron emission tomography\/ computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25320","article-title":"Liver transplantation today: Where we are now and where we are going","volume":"24","author":"Bodzin","year":"2018","journal-title":"Liver Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe - results and trends in patient selection","volume":"257","author":"LeTreut","year":"2013","journal-title":"Ann Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02233.x","article-title":"Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: An 85-case French multicentric report","author":"LeTreut","year":"2008","journal-title":"Am J Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1669936","article-title":"Liver transplantation for neuroendocrine tumors: What have we learned","volume":"38","author":"Lim.","year":"2018","journal-title":"Semin Liver Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.04.010","article-title":"Liver transplant for metastatic neuroendocrine tumors: a single-center experience in Hungary","author":"Korda","year":"2019","journal-title":"Transplantation"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20702","article-title":"Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria for improve survival","volume":"12","author":"vanVilsteren","year":"2006","journal-title":"Liver Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.6002\/ect.2019.0154","article-title":"Liver transplant for metastatic neuroendocrine tumors: A single-center report of 15 cases","volume":"19","author":"Moradi","year":"2021","journal-title":"Exp Clin Transplantaion"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000723","article-title":"Variable use of MELD exception points in patients with neuroendocrine tumors metastatic to the liver and its impact on patient outcomes","volume":"38","author":"Nobel","year":"2015","journal-title":"Transplantation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1001163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T11:12:15Z","timestamp":1675941135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1001163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":46,"alternative-id":["10.3389\/fonc.2022.1001163"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1001163","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"article-number":"1001163"}}